NYSEAMERICAN:ARMP Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis $1.89 +0.02 (+1.07%) Closing price 05/23/2025 04:10 PM EasternExtended Trading$1.92 +0.04 (+1.85%) As of 05/23/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Armata Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.81▼$2.1950-Day Range$0.90▼$2.3752-Week Range$0.90▼$3.42Volume84,087 shsAverage Volume68,608 shsMarket Capitalization$68.38 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company OverviewArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.Read More… Armata Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreARMP MarketRank™: Armata Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArmata Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageArmata Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Armata Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Armata Pharmaceuticals are expected to decrease in the coming year, from ($0.95) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Armata Pharmaceuticals is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Armata Pharmaceuticals is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Armata Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.07% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Armata Pharmaceuticals has recently increased by 19.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArmata Pharmaceuticals does not currently pay a dividend.Dividend GrowthArmata Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.07% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Armata Pharmaceuticals has recently increased by 19.05%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.13 News SentimentArmata Pharmaceuticals has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Armata Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ARMP on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders85.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.57% of the stock of Armata Pharmaceuticals is held by institutions.Read more about Armata Pharmaceuticals' insider trading history. Receive ARMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARMP Stock News HeadlinesArmata Pharmaceuticals Q4 EPS Reduced by HC WainwrightMay 22 at 1:51 AM | americanbankingnews.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Given New $9.00 Price Target at HC WainwrightMay 21 at 2:43 AM | americanbankingnews.comMemorial Day Sale! 82% Off Disruptors and Dominators!Nvidia's robot breakthrough, unveiled by CEO Jensen Huang at CES, could spark a $24T revolution. He said the "ChatGPT moment" for robotics is near. I believe the lives of 65M Americans could be impacted – this year. And one $7 stock could be the biggest winner.May 24, 2025 | Weiss Ratings (Ad)Armata Pharmaceuticals Insider Trading Activity | AMEX:ARMP | BenzingaMay 20, 2025 | benzinga.comArmata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus BacteremiaMay 19, 2025 | prnewswire.comArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deArmata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate UpdateMay 14, 2025 | prnewswire.comArmata Pharmaceuticals secures additional DoD fundingMay 3, 2025 | uk.investing.comSee More Headlines ARMP Stock Analysis - Frequently Asked Questions How have ARMP shares performed this year? Armata Pharmaceuticals' stock was trading at $2.00 at the beginning of 2025. Since then, ARMP shares have decreased by 5.5% and is now trading at $1.89. View the best growth stocks for 2025 here. How were Armata Pharmaceuticals' earnings last quarter? Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.02. The business had revenue of $1.23 million for the quarter, compared to analysts' expectations of $0.90 million. How do I buy shares of Armata Pharmaceuticals? Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Armata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Altimmune (ALT), Vaxart (VXRT), Pfizer (PFE), Advanced Micro Devices (AMD), Co-Diagnostics (CODX) and Amarin (AMRN). Company Calendar Last Earnings11/14/2023Today5/24/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:ARMP CIK921114 Webwww.armatapharma.com Phone(310) 655-2928Fax310-665-2963Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$9.00 Low Stock Price Target$9.00 Potential Upside/Downside+376.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,040,000.00 Net MarginsN/A Pretax Margin-756.59% Return on EquityN/A Return on Assets-60.91% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual Sales$4.53 million Price / Sales15.09 Cash FlowN/A Price / Cash FlowN/A Book Value($0.89) per share Price / Book-2.12Miscellaneous Outstanding Shares36,180,000Free Float5,247,000Market Cap$68.38 million OptionableNot Optionable Beta0.87 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSEAMERICAN:ARMP) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMemorial Day Sale! 82% Off Disruptors and Dominators!Jensen Huang recently gave the keynote speech at the Consumer Electronics Show in Las Vegas. When the Nvidi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Armata Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.